Form 8-K EXOZYMES INC. For: Jun 30
Tweet
Share
E-mail
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
Current Report Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
(Address of principal executive offices and zip code)
Registrant’s
telephone number, including area code:
Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Exchange Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
| Item 1.01 | Entry into a Material Definitive Agreement. |
Underwritten Offering
Securities Placement
On June 30, 2026, eXoZymes Inc. (the “Company”) entered into a Placement Agent Agreement (the “Placement Agreement”), with Public Ventures LLC, doing business as MDB Capital (“MDB”), as the exclusive placement agent pursuant to which the Company authorized the sale to an investor of up to an aggregate of 35,555 units (the “Units”), consisting of 71,110 shares (the “Shares”) of its common stock, par value $0.000001 per share (the “Common Stock”), and 35,555 warrants to purchase up to an aggregate of 35,555 shares of our common stock (the “Warrants) (the “Offering”). The price per Unit was $18.00. The Shares and Warrants were immediately separable and were issued separately but will be purchased together as a unit. The purchase price of one Share will be the equivalent of $8.99 and of the Warrant $0.02.
The securities offered and sold in the Offering had the same terms as the securities sold in the firm commitment underwriting led by MDB on June 5, 2026.
The Offering closed on June 30, 2026. The gross proceeds to the Company from the Offering were $639,990, before commissions of $44,799 and other expenses of approximately $30,000. The net proceeds will be used to further develop the opportunities associated with the N-trans-caffeoyltyramine (NCT) business and products developed under the NCT technology of the Company, next in line products, research and development and general corporate purposes, working capital and capital expenditures.
The Placement Agreement contains customary representations, warranties and agreements by the Company, indemnification obligations of the Company, including for liabilities arising under the Securities Act of 1933, as amended (the “Securities Act”), and other obligations of the parties and termination provisions. The representations, warranties and covenants contained in the Placement Agreement were made only for the purposes of such agreement and as of the specific dates, were solely for the benefit of the parties to such agreement and may be subject to limitations agreed upon by the contracting parties. MDB, as placement agent, was issued a warrant to purchase 10,666 shares of common stock, exercisable at $11.24 per share, from December 30, 2026, until June 30, 2031.
The investor in the Offering signed a securities purchase agreement (the “Investor Agreement”), which contains customary representations, warranties and agreements by the Company and closing procedures.
The Offering was made pursuant to the Company’s effective shelf registration statement on Form S-3 (File No. 333-292781), which was declared effective on January 23, 2026, a related base prospectus and final prospectus supplement thereunder dated June 30, 2026.
Warrant Terms
The Warrants were issued pursuant to the Warrant Agent Agreement, dated June 5, 2026, as modified. Each Warrant will be exercisable commencing June 5, 2027, at an exercise price of $11.24 per share (“Exercise Price”) and will expire on June 5, 2031. The Warrants may be called for redemption, commencing June 5, 2027, provided that there is an effective registration statement for the resale of the shares of common stock underlying the Warrants. Subject to the foregoing condition, the Company may only call the Warrants for redemption, once the Warrants are exercisable, if and when a share of common stock trades at or greater than $17.98 on any twenty (20) trading days during any thirty (30) trading day period. Notice of redemption shall be given not less than 30 days prior to the date of redemption. Warrant holders will be able to exercise their Warrants through the date of redemption. The Warrant redemption price is $.01 per Warrant. There will be no broker protect period.
The Exercise Price of a Warrant will be reset (the “Warrant Reset”), in addition to any other adjustments thereto as provided herein, in the event the Company sells in a public or private offering (other than pursuant to an equity incentive plan adopted by the board of directors) before June 5, 2027 (the “Commencement Date”), additional shares of common stock, or preferred stock or other securities convertible into shares of common stock, at a per share price (or equivalent) at less than the per share price of $8.99. In that event, the Exercise Price will reset to a per share price of $0.001. Once reset, there will be no further resets for subsequent offerings.
To qualify for the Warrant Reset, if any, an original purchaser of a unit in this Offering (the “Original Purchaser”) must be able to demonstrate that it has held all the shares of common stock included in the Units it acquired in the Offering (the “Offered Shares”) up until the date of the Warrant Reset event, if any (the “Holding Period”). If there is a Warrant Reset, then the Company will give prompt notice of the Warrant Reset and the date of the event to the holders of Warrants, and the holders of the Warrants that qualify as having been an Original Purchaser holding all their shares of common stock acquired in the Offering for the full Holding Period, will be required to submit to the Warrant Agent their outstanding Warrants for cancellation and re-issue with the adjusted terms within thirty (30) calendar days of the date of the Company notice. Failure to submit timely the Warrant for exchange will terminate the right to the Warrant Reset. The new warrant will be issued by the Warrant Agent. After the date of the Warrant Reset, the Holding Period will terminate and the Original Purchaser will have no further requirement to hold the Offered Shares.
Except for those permitted transfers described below, to qualify for the Warrant Reset, if any, the Offered Shares may not be transferred, assigned, subject to pledge or be otherwise alienated (which includes having the Offered Shares subject to market options, swaps and other derivative securities that transfer the value thereof) during the Holding Period. Except for the permitted transfers, the Original Purchaser will immediately and automatically forfeit the Warrant Reset provision if the Original Purchaser transfers, assigns pledges or otherwise alienates the Offered Shares during the Holding Period. Notwithstanding the foregoing restrictions the following transfers of Offered Shares during the Holding Period are allowed:
| ● | Transfers made by will or operation of law on the Original Purchaser’s death, to the Original Purchaser’s spouse, ex-spouse, child, grandchild, stepchild, or other testamentary dispositions, or | |
| ● | A transfer made pursuant to a court order or bona-fide settlement agreement of the parties with a beneficial interest in the Offered Shares, or | |
| ● | A transfer made to a trust or other similar estate planning entity for the benefit of the Original Purchaser and immediate members of his family, or | |
| ● | A transfer made pursuant to a “required minimum distribution” from an account held by the Original Purchaser, or | |
| ● | A transfer or transfers made on liquidation of any corporation, trust or other entity that is the Original Purchaser. |
To retain the benefit of the Warrant Reset provision upon any of these occurrences the transferee must notify the Company and the transfer agent, if applicable, on transfer and present reasonable proof or support for the allowed transfer, such as a death certificate, court order or certificate of liquidation from an appropriate office of the state government, executed agreement and other documents reasonably requested and acceptable in the judgement of the Company.
On June 30, 2026, the Company and VStock Transfer LLC, the transfer agent for the Warrants, entered into a modification of the Warrant Agent Agreement, to increase the coverage for the newly issued Warrants.
Documents Filed
The legal opinion of Spencer Fane LLP relating to the Shares and Warrants is filed herewith as Exhibit 5.1.
The foregoing descriptions of the terms and conditions of the Placement Agreement, the Warrant Agent Agreement and its modification, Form of Warrant to be issued to the Placement Agent, and the Investor Agreement do not purport to be complete and are qualified in its entirety by the full text of each of such documents, copies of which are included as Exhibits 10.1, 10.2, 10.3, 10.4, and 10.5, respectively, and incorporate by reference herein.
| Item 9.01. | Financial Statements and Exhibits. |
(d) Exhibits
| * | Filed herewith |
| ** | Previously filed |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: July 1, 2026 | EXOZYMES INC. | |
| By | /s/ Fouad Nawaz | |
| Fouad Nawaz, | ||
| Vice President, Finance | ||
ATTACHMENTS / EXHIBITS
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- TowneBank Reports Second Quarter 2026 Earnings
- Ascletis Announces Oral Discussion of ASC36_35 FDC Preclinical Data Demonstrating Superior Weight Loss to Eloralintide/Tirzepatide Combination at the 62nd European Association for the Study of Diabete
- JINRO Unveils First Global Campaign "My Favorite JINRO" with V of BTS
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
